FDA approves first mRNA-based flu vaccine | CNN

mRNA cancer vaccine succeeded in Phase 3 melanoma trial, Moderna and Merck say

The vaccine reportedly thwarted the cancer's return and spread.

F.D.A. Approves New Covid Vaccines, and They Should Be Available Soon

The shots have been approved for people 65 and older, and for younger people with underlying conditions. Others may be able to get them off label.

Pancreatic cancer mRNA vaccine shows lasting results in an early trial

Scientists caution that more research is needed, but nearly all of the patients who responded to the personalized vaccine are still alive six years later.

What to Know About New Covid Vaccines for Fall 2026

The shots have been approved for people 65 and older, and for younger people with underlying conditions. Others may be able to get them off label.

Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%

Markers released top-line results today after previously reporting the trial succeeded.

COVID-19 Vaccine Effectiveness and Safety for the 2026-2027 Respiratory Season

Importance SARS-CoV-2 remains a substantial cause of respiratory illness, morbidity, and mortality. Evidence to date has demonstrated that COVID-19 vaccines reduce the risk of severe disease, including hospitalization and death. Objective This systematic review identifies and summarizes newly published studies reporting on the effectiveness and safety of COVID-19 vaccines and COVID-19 epidemiology in the US. Evidence Review Cochrane Central Register of Controlled Trials, PubMed/MEDLINE, Embase, and Scopus were searched from August 1, 2025, through June 29, 2026. Studies were eligible if they reported on the effectiveness, efficacy, or safety of a US-licensed COVID-19 vaccine or SARS-CoV-2 epidemiology in the US. Findings From 11 829 identified references, 155 publications were eligible (15 randomized clinical trials, 84 observational studies with a comparator group, 38 product safety studies without a comparator group [single group], and 18 descriptive studies of disease burden). Consistent with prior evidence, studies reported that updated COVID-19 vaccines were associated with a reduction in the risk of hospitalization among both older adults (≥65 years; vaccine effectiveness [VE], 53.0%; 95% CI, 37.0%-65.0%; 2025-2026 season) and adults (18-64 years; VE, 54.0%; 95% CI, 1.0%-78.0%; 2024-2025 season). Maternal vaccination was associated with reduced risk of COVID-19–associated emergency department/urgent care encounters among individuals vaccinated (VE, 58.0%; 95% CI, 24.0%-77.0%) and with fewer COVID-19–related hospital contacts in the first 2 months of life among infants born subsequently (VE range, 50.0%-54.0%), regardless of trimester of vaccination. Vaccination was also associated with a significant reduction in COVID-19–related pediatric emergency department visits (9 months to 4 years; VE, 76.0%; 95% CI, 58.0%-87.0%). Vaccination was associated with a reduced risk of critical COVID-19 illness (intensive care unit admission or death) in immunocompromised adults (VE range, 32.0%-53.0%, depending on condition and other factors). Health care personnel who received 3 to 5 vaccine doses were less likely to develop laboratory-confirmed COVID-19 illness (VE, 41.0%; 95% CI, 34.0%-47.0%) and postacute COVID-19 symptoms (VE, 57.0%; 95% CI, 46.0%-66.0%) compared with those who received only 2 doses. Across adverse events of special interest (eg, stroke, thrombosis, myocarditis), safety profiles were consistent with those of previous reviews. No identified studies conducted under the updated guidance on extended dosing intervals for the primary series reported an increased risk of myocarditis or pericarditis. No new safety signals were reported in the recently published studies eligible for this updated review of US-licensed COVID-19 vaccines. Conclusions and Relevance COVID-19 vaccines were consistently associated with a reduction in the risk of hospitalization and other outcomes, including among individuals at high risk of severe COVID-19, such as infants, and those who were pregnant. No new safety concerns were identified.

COVID-19 Vaccine Effectiveness and Safety for the 2026-2027 Respiratory Season

This Special Communication aims to identify and summarize the most recently published evidence evaluating the effectiveness and safety of US-licensed COVID-19 vaccines and report on the epidemiology of SARS-CoV-2 in the US.

A New Hantavirus Vaccine Is in the Works

Since 2023, Moderna and Korea University have been developing a new mRNA vaccine for hantavirus. The work has been promising so far, but a finished product isn't likely coming any time soon.

mRNA vaccine for melanoma reduces relapse after therapy, trial finds

A personalized mRNA cancer vaccine combined with immunotherapy cuts the risk of recurrence by nearly half, researchers say.

Agency, The Only Vaccine for Big Tech | Alliance for Self-Directed Education

How can fostering agency help safeguard our kids?

Making Vaccine — LessWrong

John made his own COVID-19 vaccine at home using open source instructions. Here's how he did it and why. …

Opinion | Treat Medicines Like Netflix Treats Shows (Published 2019)

Australia seems to have found a way to entice Big Pharma into making essential new medicines affordable. Why can’t the United States?

Bird Flu Is Raging on a Mink Farm. It Could Spark a Human Pandemic, Experts Say, but Officials Won’t Act. — ProPublica

Federal officials brushed off the issue as Utah prioritized the fur industry’s interests. Little has been done to stop the spread of the virus and ensure it can’t spread to humans, a failure that experts called “irresponsible” and “astounding.”

Vascular and inflammatory diseases after COVID-19 infection and vaccination in children and young people in England: a retrospective, population-based cohort study using linked electronic health records

Children and young people have higher risks of rare vascular and inflammatory diseases up to 12 months after a first COVID-19 diagnosis and higher risk of rare myocarditis or pericarditis up to 4 weeks after a first BNT162b2 vaccine, although the risk following vaccination is substantially lower than the risk following infection. These findings are of great importance for national policy makers and caregivers considering vaccination consent for children, and support the public health strategy of COVID-19 vaccination in children and young people to mitigate the more frequent and persistent risks associated with SARS-CoV-2 infection.

Vascular and inflammatory diseases after COVID-19 infection and vaccination in children and young people in England: a retrospective, population-based cohort study using linked electronic health records

Children and young people have higher risks of rare vascular and inflammatory diseases up to 12 months after a first COVID-19 diagnosis and higher risk of rare myocarditis or pericarditis up to 4 weeks after a first BNT162b2 vaccine, although the risk following vaccination is substantially lower than the risk following infection. These findings are of great importance for national policy makers and caregivers considering vaccination consent for children, and support the public health strategy of COVID-19 vaccination in children and young people to mitigate the more frequent and persistent risks associated with SARS-CoV-2 infection.